Persist or Resist: Immune Checkpoint Inhibitors in EGFR-mutated NSCLC

Overview

Journal Cancer Sci

Specialty Oncology

Date 2024 Dec 14

PMID 39673162

Authors

Pengcheng Zhu

Zhitong Li

Yuxiang Sun

Tongyan Liu

Rong Yin

Affiliations

Soon will be listed here.

Abstract

Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), especially third-generation TKIs, have significantly improved the progression-free survival and overall survival of non-small cell lung cancer (NSCLC) patients with EGFR mutation, TKI resistance is inevitable for most patients. Over the past few years, immune checkpoint inhibitors (ICIs) have significantly improved the survival for EGFR-wild type NSCLC patients. However, no significantly improved benefits were observed with ICI monotherapy in EGFR-mutated patients. EGFR-mutated NSCLC shows more heterogeneity in tumor mutational burden (TMB), programmed cell death-ligand 1 (PD-L1), and immune microenvironment characteristics. Whether ICIs are suitable for EGFR-mutated NSCLC patients remains to be elucidated. In this review, we summarized clinical trials of ICIs or combined therapy in EGFR-mutated NSCLC patients. We further discussed the factors determining the efficacy of ICIs in EGFR-mutated NSCLC patients, the mutation subtypes and microenvironment characteristics of potential responders. More importantly, we provided insights into areas worth further investigation in the future.

Citing Articles

Persist or resist: Immune checkpoint inhibitors in EGFR-mutated NSCLC.

Zhu P, Li Z, Sun Y, Liu T, Yin R Cancer Sci. 2024; 116(3):581-591.

PMID: 39673162 PMC: 11875763. DOI: 10.1111/cas.16428.

References

Rachiglio A, Fenizia F, Piccirillo M, Galetta D, Crino L, Vincenzi B . The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. Cancers (Basel). 2019; 11(3). PMC: 6468673. DOI: 10.3390/cancers11030341. View

Ma L, Diao B, Huang Z, Wang B, Yu J, Meng X . The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Commun (Lond). 2021; 41(12):1314-1330. PMC: 8696228. DOI: 10.1002/cac2.12229. View

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View

Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2):154-62. PMC: 4132036. DOI: 10.1097/JTO.0000000000000033. View

Kobayashi Y, Mitsudomi T . Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016; 107(9):1179-86. PMC: 5021039. DOI: 10.1111/cas.12996. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K . EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019; 18(1):165. PMC: 6864970. DOI: 10.1186/s12943-019-1073-4. View

Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M . Impact of Mutations on Outcome in -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clin Cancer Res. 2016; 23(9):2195-2202. DOI: 10.1158/1078-0432.CCR-16-0966. View

10.

VanderLaan P, Rangachari D, Mockus S, Spotlow V, Reddi H, Malcolm J . Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017; 106:17-21. PMC: 5351777. DOI: 10.1016/j.lungcan.2017.01.011. View

11.

Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S . PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS One. 2016; 11(4):e0153954. PMC: 4841565. DOI: 10.1371/journal.pone.0153954. View

12.

Pollack B . EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?. Oncoimmunology. 2012; 1(1):71-74. PMC: 3376950. DOI: 10.4161/onci.1.1.18073. View

13.

Kumagai S, Koyama S, Nishikawa H . Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 2021; 21(3):181-197. DOI: 10.1038/s41568-020-00322-0. View

14.

Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J . An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010; 17(3):298-310. PMC: 2897158. DOI: 10.1016/j.ccr.2009.12.047. View

15.

Passarelli A, Aieta M, Sgambato A, Gridelli C . Targeting Immunometabolism Mediated by CD73 Pathway in -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance. Front Immunol. 2020; 11:1479. PMC: 7371983. DOI: 10.3389/fimmu.2020.01479. View

16.

Yang W, Chen N, Li L, Chen X, Liu X, Zhang Y . Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations. Lung Cancer (Auckl). 2020; 11:59-71. PMC: 7490071. DOI: 10.2147/LCTT.S262822. View

17.

Gettinger S, Rizvi N, Chow L, Borghaei H, Brahmer J, Ready N . Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(25):2980-7. PMC: 5569692. DOI: 10.1200/JCO.2016.66.9929. View

18.

Reck M, Mok T, Nishio M, Jotte R, Cappuzzo F, Orlandi F . Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019; 7(5):387-401. DOI: 10.1016/S2213-2600(19)30084-0. View

19.

Lohinai Z, Hoda M, Fabian K, Ostoros G, Raso E, Barbai T . Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. J Thorac Oncol. 2015; 10(5):738-746. DOI: 10.1097/JTO.0000000000000492. View

20.

Yang J, Shepherd F, Kim D, Lee G, Lee J, Chang G . Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019; 14(5):933-939. DOI: 10.1016/j.jtho.2019.02.001. View